{"bill": {"#text": "\n\t", "form": {"current-chamber": {"#tail": "\n\t\t", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": "\n\t\t", "congress": {"#tail": "\n\t\t", "#text": "113th CONGRESS"}, "#tail": "\n\t", "legis-num": {"#tail": "\n\t\t", "#text": "H. R. 5805"}, "official-title": {"#tail": "\n\t", "#text": "To amend the Federal Food, Drug, and Cosmetic Act with respect to expanding access for breakthrough\n\t\t\t drugs, and for other purposes."}, "session": {"#tail": "\n\t\t", "#text": "2d Session"}, "distribution-code": {"#tail": "\n\t\t", "@display": "yes", "#text": "I"}, "action": {"action-date": {"#tail": "\n\t\t\t", "@date": "20141208", "#text": "December 8, 2014"}, "#tail": "\n\t\t", "action-desc": {"#tail": "\n\t\t", "#text": "\n        ", "sponsor": {"#tail": " introduced the following bill; which was referred to the ", "#text": "Mr. McCaul", "@name-id": "M001157"}, "committee-name": {"#tail": "\n      ", "@committee-id": "HIF00", "#text": "Committee on Energy and Commerce"}}, "#text": "\n\t\t\t"}, "legis-type": {"#tail": "\n\t\t", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-House", "@bill-type": "olc", "@dms-id": "H7270ACFEF09D4E1D8CB3714E3F6B9B0A", "@public-private": "public", "legis-body": {"#tail": "\n", "@style": "OLC", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n\t\t", "quote": [{"short-title": {"#tail": "\n        ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "act", "#text": "Andrea Sloan Compassionate Use Reform and Enhancement Act", "@value": "Andrea Sloan Compassionate Use Reform and Enhancement Act", "@proposed": "true"}, "#text": "\n            "}, "#tail": " or the ", "#text": "\n          "}, {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n        ", "@entity-type": "act", "#text": "Andrea Sloan CURE Act", "@value": "Andrea Sloan CURE Act", "@proposed": "true"}, "#text": "\n          "}], "#text": "This Act may be cited as the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "H039928F01FE84C24B4F82AD7DDC75E9F"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 561 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:561"}, "@entity-type": "law-citation", "#text": "\n          ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n        ", "@entity-type": "uscode", "#text": "21 U.S.C. 360bbb", "@value": "usc/21/360bbb"}, "@parsable-cite": "usc/21/360bbb", "#text": "\n          ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n      ", "#text": "Expanded access policy as condition of expedited approval"}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "by redesignating subsections (d) and (e) as subsections (e) and (f), respectively; and"}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "@id": "H10446810358F427BB7FA40AD97854C11", "#text": "\n        "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t\t", "#text": "by inserting after subsection (c) the following new subsection:"}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n\t\t\t", "subsection": {"#tail": "\n          ", "enum": {"#tail": "\n            ", "#text": "(d)"}, "header": {"#tail": "\n\t\t\t\t\t\t", "#text": "Expanded access policy required for covered breakthrough drugs"}, "paragraph": [{"#tail": "\n            ", "@id": "H589AF154BBA74388BCE16D565F6BE974", "enum": {"#tail": "\n              ", "#text": "(1)"}, "header": {"#tail": "\n              ", "#text": "In general"}, "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " and make publicly available the policy of the sponsor\n\t\t\t with respect to requests submitted under subsection (b). In the case of\n\t\t\t such a policy under which the sponsor accepts such requests, such policy\n\t\t\t shall include\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "With respect to a qualified breakthrough drug, not later than 30 days after the date on which the\n\t\t\t drug meets the definition of a covered breakthrough drug (as specified in\n\t\t\t paragraph (2)), the sponsor of the covered breakthrough drug shall submit\n\t\t\t to the ", "@display-inline": "yes-display-inline"}, "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "a single point of contact who receives and processes such requests;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "H7FDCFCC2D13249759D93F4BEAC017754", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "procedures for making such requests;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "HFDEA7578EB244A78BE05C084385FC281", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "the minimum criteria for the sponsor\u2019s consideration or approval of such requests; and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "@id": "HF468D28C6BA64B528446126053F37214", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "the amount of time the sponsor anticipates will be necessary to make a decision on such requests.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(D)"}, "@id": "H63B8712738264051B5B3EDCC2ADEAACC", "#text": "\n                "}]}, {"#tail": "\n          ", "@id": "HB1693DCD6899421DBAC053A1544634F9", "enum": {"#tail": "\n              ", "#text": "(2)"}, "header": {"#tail": "\n              ", "#text": "Covered breakthrough drug"}, "text": {"#tail": "\n\t\t\t\t\t\t\t", "term": {"#tail": " means a drug\u2014", "#text": "covered breakthrough drug"}, "#text": "In this subsection, the term "}, "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ";", "@entity-type": "act", "#text": "section 506", "@value": "Federal Food, Drug, and Cosmetic Act/s:506"}, "#text": "that is designated as a breakthrough therapy or as a fast track product or is approved under\n\t\t\t accelerated approval under ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "H2CA431E0128E48F88A24C71B9D4525FD", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " as a qualified infectious disease product; or", "@entity-type": "act", "#text": "section 505E(d)"}, "#text": "that is designated under "}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "HB14B22670B23467DAEC8C8C9D0F8B490", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n              ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " or ", "@entity-type": "act", "#text": "section 524", "@value": "Federal Food, Drug, and Cosmetic Act/s:524"}, {"#tail": ".", "@entity-type": "act", "#text": "529", "@value": "Federal Food, Drug, and Cosmetic Act/s:529"}], "#text": "the sponsor of which is awarded a priority review voucher under "}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "@id": "HC4A57602E1DE49048F278B18786D1C6C", "#text": "\n                "}]}], "#text": "\n            ", "@id": "H2D9F9B8006A049568047A82B76B432E0"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t", "@id": "H44BFFAD4D3404CD488C0032BE58FFDFF"}, "#text": "\n        ", "@id": "H4F6853B4A55646D6915F2DC7BD94F920"}], "#text": "\n      ", "@id": "HE73C163BA3A8496EA6E7D64C2D901E90"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", is further amended\u2014", "@entity-type": "act", "#text": "section\n\t\t\t 2", "@value": "Andrea Sloan CURE Act/s:2", "@proposed": "true"}, "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ", as amended by ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 561 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:561"}, "@entity-type": "law-citation", "#text": "\n          ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n        ", "@entity-type": "uscode", "#text": "21 U.S.C. 360bbb", "@value": "usc/21/360bbb"}, "@parsable-cite": "usc/21/360bbb", "#text": "\n          ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": "\n      ", "#text": "Notification of submitters of compassionate use requests"}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ") as subsections (f) and\n\t\t\t (g), respectively; and", "@entity-type": "act", "#text": "section 2(1)", "@value": "Andrea Sloan CURE Act/s:2/p:1", "@proposed": "true"}, "#text": "by redesignating subsections (e) and (f) (as redesignated by "}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "@id": "H6939874A7DBE42E5ACC4E8765354B80B", "#text": "\n        "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ") the following new subsection:", "@entity-type": "act", "#text": "section 2(2)", "@value": "Andrea Sloan CURE Act/s:2/p:2", "@proposed": "true"}, "#text": "by inserting after subsection (d) (as inserted by "}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n\t\t\t", "subsection": {"#tail": "\n          ", "text": {"#tail": "\n          ", "#text": "In the case of the denial by a manufacturer or distributor of a request under subsection (b), not\n\t\t\t later than 5 days after the date of such denial, the manufacturer or\n\t\t\t distributor, as applicable, shall submit to the person (or physician) who\n\t\t\t made the request written notice of the denial, including an explanation\n\t\t\t for the denial.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(e)"}, "header": {"#tail": "\n            ", "#text": "Notification of submitters of requests"}, "#text": "\n            ", "@id": "H4D984BE1DCC14405B4C1FA4E8D3A8DEF"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t", "@id": "HECAA81D2488546339D40246C5341BD85"}, "#text": "\n        ", "@id": "HC8337298FAB146ACA7CA082A43FAF70C"}], "#text": "\n      ", "@id": "H357BDA3AB04544B6B4B58F772B1366C7"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall submit to the ", "@entity-type": "federal-body", "#text": "Comptroller General of the United States", "@entity-id": "0500"}, {"#tail": " and the ", "@entity-type": "committee", "#text": "Committee on\n\t\t\t Energy and Commerce of the House of Representatives", "@entity-id": "HIF00"}, {"#tail": " a report containing a\n\t\t\t qualitative analysis of the extent to which individual patients have\n\t\t\t access to investigational drugs pursuant to ", "@entity-type": "committee", "#text": "Committee on\n\t\t\t Health, Education, Labor and Pensions of the Senate", "@entity-id": "SSHR00"}, {"#tail": " shall conduct a qualitative analysis of the following:", "@entity-type": "federal-body", "#text": "Comptroller General", "@entity-id": "0500"}], "#text": "Not later than 180 days after the date of the enactment of this Act and each year thereafter, the\n\t\t\t ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " and\n\t\t\t recommendations for improving such access. In preparing such report, the\n\t\t\t ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "subsection (b) of section 561\n\t\t\t of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:561/ss:b"}, "@entity-type": "law-citation", "#text": "\n          ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n        ", "@entity-type": "uscode", "#text": "21 U.S.C. 360bbb", "@value": "usc/21/360bbb"}, "@parsable-cite": "usc/21/360bbb", "#text": "\n          ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "4."}, "header": {"#tail": "\n      ", "#text": "GAO qualitative analysis on individual patient access to unapproved therapies and diagnostics"}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Whether there are any identifiable patterns in requests submitted under subsection (b) of such\n\t\t\t section, such as the types of indications for which requests for\n\t\t\t individual patient access are sought or the reasons for the denial of such\n\t\t\t requests.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "@id": "H3EF996F7AD5F471AAA0D5412BA737781", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "What the primary barriers are to drug sponsors granting requests for individual patient access.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "@id": "H973DAC138CAA452D9016AE118C46D818", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " evaluates safety and efficacy data submitted in connection with such requests.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "How the "}, "enum": {"#tail": "\n        ", "#text": "(3)"}, "@id": "HD6BD9E2DC84144FF9486C867EAD4E894", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "The amount of time that\u2014"}, "enum": {"#tail": "\n        ", "#text": "(4)"}, "#text": "\n        ", "@id": "H386D564BA4EC43F7A398FFB4CE6FDC60", "subparagraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "a physician typically takes to complete the paperwork necessary to make such a request;"}, "enum": {"#tail": "\n          ", "#text": "(A)"}, "@id": "HCBED7560B65D43D5ABF2A5AA5157F0C2", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "a drug sponsor takes to process such a request and to issue a decision with respect to the request;\n\t\t\t and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(B)"}, "@id": "H8D4504FE12384881B8677E0B4E3DF1B9", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " takes to process such a request and to issue a decision with respect to the request.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "the "}, "enum": {"#tail": "\n          ", "#text": "(C)"}, "@id": "H8084BDCF94C847298EE9084439065F69", "#text": "\n          "}]}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "How regulations, guidance, policies, or practices may be modified, streamlined, expanded, or\n\t\t\t discontinued to reduce or prevent delays in approving such requests."}, "enum": {"#tail": "\n        ", "#text": "(5)"}, "@id": "HDEFAF21B920D4F7FBDDC5BEF5F606889", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "The number of such requests that, for the period covered by the report\u2014"}, "enum": {"#tail": "\n        ", "#text": "(6)"}, "#text": "\n        ", "@id": "H3EC79BC11141491F9DE005898BBA5AA7", "subparagraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ";", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, "#text": "were approved by drug sponsors and the "}, "enum": {"#tail": "\n          ", "#text": "(A)"}, "@id": "H243E034EB60540D1AC06075EBE2481FD", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "; and", "@entity-type": "federal-body", "#text": "Food and Drug Administration", "@entity-id": "7524"}, "#text": "were approved by drug sponsors but denied by the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(B)"}, "@id": "H23E227CDC87C43E19964ADD3A7E3351D", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "were denied by drug sponsors."}, "enum": {"#tail": "\n          ", "#text": "(C)"}, "@id": "HC5567C9B5B1741CDAA1D212897591188", "#text": "\n          "}]}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ",\n\t\t\t including requests for emergency use, intermediate-size patient\n\t\t\t populations, and large patient populations under a specified indication.", "@entity-type": "act", "#text": "section 561", "@value": "Federal Food, Drug, and Cosmetic Act/s:561"}, "#text": "How to encourage drug sponsors to grant requests for expanded access under such "}, "enum": {"#tail": "\n        ", "#text": "(7)"}, "@id": "HBA0EF9A8BCDA4B4C9879D2EFD15DB58F", "#text": "\n        "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " as a result of individual use\n\t\t\t of an investigational drug or investigational device under such ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " affected the development or approval of any drug or device.", "@entity-type": "act", "#text": "section\n\t\t\t 561", "@value": "Federal Food, Drug, and Cosmetic Act/s:561"}], "#text": "Whether and to what extent adverse events reported to the "}, "enum": {"#tail": "\n        ", "#text": "(8)"}, "@id": "H86A6BA85D7084E1D96B28CC826BC0BAD", "#text": "\n        "}], "#text": "\n      ", "@id": "H4C53F6B2918941FA894EF8A517528DDB"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "5."}, "header": {"#tail": "\n\t\t\t", "#text": "Expanded access task force"}, "subsection": [{"#tail": "\n      ", "text": {"{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall establish a task force within the ", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, {"#tail": " to explore mechanisms for improving the access\n\t\t\t individual patients have to investigational drugs pursuant to ", "@entity-type": "federal-body", "#text": "Department of\n\t\t\t Health and Human Services", "@entity-id": "7500"}, {"#tail": "\n\t\t\t submits the first report required under ", "@entity-type": "federal-body", "#text": "Comptroller General of the United States", "@entity-id": "0500"}, {"#tail": ", the Task Force shall be\n\t\t\t convened.", "@entity-type": "act", "#text": "section 4", "@value": "Andrea Sloan CURE Act/s:4", "@proposed": "true"}], "#tail": "\n\t\t\t", "quote": [{"#tail": " (in this section referred to as the ", "#text": "Expanded Access Task Force"}, {"#tail": "). Not later than 90 days after the date on which the ", "#text": "Task Force"}], "{http://namespaces.cato.org/catoxml}entity": {"#tail": ", to be known as the ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "subsection\n\t\t\t (b) of section 561 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:561/ss:b"}, {"#tail": ")", "@entity-type": "uscode", "#text": "21 U.S.C.\n\t\t\t 360bbb", "@value": "usc/21/360bbb"}], "@entity-type": "law-citation", "#text": "\n            "}, "italic": {"#tail": "The "}, "@display-inline": "yes-display-inline", "#text": "\n          "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Establishment"}, "#text": "\n        ", "@id": "H2B10AFABAAEA4052B89EF76463E6C034"}, {"#tail": "\n      ", "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n\t\t\t\t", "#text": "Membership"}, "paragraph": [{"#tail": "\n        ", "@id": "HEB65C58532514181A633104B07D3F94E", "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "Composition"}, "text": {"#tail": "\n\t\t\t\t\t", "#text": "The Task Force shall be composed of not more than 9 voting members appointed as follows:", "@display-inline": "yes-display-inline"}, "#text": "\n          ", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-parent-id": "0050", "@entity-type": "federal-body", "#text": "Speaker of the House of\n\t\t\t Representatives", "@value": "Speaker of the House of Representatives"}, "#text": "One member to serve as Chairman of the Task Force, appointed by the "}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "H6360113BA1BD44178B303C16C304A532", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", appointed by the ", "@entity-type": "federal-body", "#text": "Department of Health and Human Services", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "federal-body", "#text": "Secretary of\n\t\t\t Health and Human Services", "@entity-id": "7500"}], "#text": "One representative from the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "@id": "H3A9FB0596A58409DA00CFBFAE735EF10", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", in\n\t\t\t consultation with the ", "@entity-type": "federal-body", "#text": "House of Representatives", "@entity-id": "0050"}, {"#tail": ", and\n\t\t\t the Chairman and the Ranking Member of the ", "@entity-parent-id": "0050", "@entity-type": "federal-body", "#text": "Minority Leader of the House of Representatives", "@value": "Minority Leader of the House of Representatives"}, {"#tail": ", including\u2014", "@entity-type": "committee", "#text": "Committee on Energy and\n\t\t\t Commerce of the House of Representatives", "@entity-id": "HIF00"}], "#text": "Four representatives appointed by the Majority Leader of the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(C)"}, "clause": [{"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "#text": "one representative of a biopharmaceutical company of less than 250 full-time employees;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n              ", "#text": "(i)"}, "@id": "HE180292012A34FEB9E5F15A121D3B555", "#text": "\n              "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "#text": "one representative of the rare disease patient community;"}, "enum": {"#tail": "\n              ", "#text": "(ii)"}, "@id": "HD2CB7020BC344A44B3D25F0F0B6107D5", "#text": "\n              "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "#text": "one representative of the health care provider community; and"}, "enum": {"#tail": "\n              ", "#text": "(iii)"}, "@id": "H0AD2FC3F9C724E99A2AA61E723753AE8", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "#text": "one bioethicist."}, "enum": {"#tail": "\n              ", "#text": "(iv)"}, "@id": "H7EF5731109264C0D9EB0A2824E9EE71D", "#text": "\n              "}], "#text": "\n            ", "@id": "H015A4C6984EF44D79438D5915DBB2D81"}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", in consultation with the ", "@entity-parent-id": "0010", "@entity-type": "federal-body", "#text": "Majority Leader of the Senate", "@value": "Majority Leader of the Senate"}, {"#tail": ", and the Chairman and the Ranking Member of the\n\t\t\t ", "@entity-parent-id": "0010", "@entity-type": "federal-body", "#text": "Minority\n\t\t\t Leader of the Senate", "@value": "Minority Leader of the Senate"}, {"#tail": ", including\u2014", "@entity-type": "committee", "#text": "Health, Education, Labor and Pensions Committee of the Senate", "@entity-id": "SSHR00"}], "#text": "Three representatives appointed by ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(D)"}, "clause": [{"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "#text": "one representative of the biopharmaceutical industry;"}, "enum": {"#tail": "\n              ", "#text": "(i)"}, "@id": "H245C54100EF949B6ABD113DB5E7B2F42", "#text": "\n              "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "#text": "one representative of the patient community; and"}, "enum": {"#tail": "\n              ", "#text": "(ii)"}, "@id": "HCA06E7CC533E450195B0C037B9282784", "#text": "\n              "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "#text": "one representative of the health care payor community."}, "enum": {"#tail": "\n              ", "#text": "(iii)"}, "@id": "H3B66041B353D43B9BC92726C576AF49F", "#text": "\n              "}], "#text": "\n            ", "@id": "HB21E9F8EDF1D4E348FEFDFED549BCCD9"}]}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "Members of the Task Force shall serve without compensation."}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n          ", "#text": "Compensation"}, "#text": "\n          ", "@id": "H555759552DD549BF8AEDAE3196CBA42B"}], "#text": "\n        ", "@id": "H21B6CC7EA1AA47068BD937205E097627"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "The Task Force shall comprehensively evaluate the access individual patients have to\n\t\t\t investigational drugs pursuant to ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ", taking into\n\t\t\t account\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "subsection (b) of section 561 of the\n\t\t\t Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:561/ss:b"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "21 U.S.C. 360bbb", "@value": "usc/21/360bbb"}, "@parsable-cite": "usc/21/360bbb", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Duties"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "the unique challenges faced by children with likely fatal diseases for which there is not a\n\t\t\t comparable or satisfactory alternative therapy available;", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "H41942AC3581742FCAD71B2495897B247", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "possible incentives for biopharmaceutical companies and providers to approve requests submitted\n\t\t\t under such subsection;"}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "H3B46C6C465CF45EA99B15F4F6FEA907F", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " interprets and takes into consideration adverse\n\t\t\t event data reported in the case of data from use under a request submitted\n\t\t\t under such subsection;", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, "#text": "how the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "@id": "H3847C139BE9B4158AD3C8A6B1DE809E7", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "ways to streamline and standardize the process for submitting requests under such subsection; and"}, "enum": {"#tail": "\n          ", "#text": "(4)"}, "@id": "HAA83E96CF1FE44A58A133D73AC6C760C", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "the costs incurred by biopharmaceutical companies for the time, effort, and delivery of\n\t\t\t investigational drugs to patients for the diagnosis, monitoring, or\n\t\t\t treatment of a serious disease or condition under such subsection."}, "enum": {"#tail": "\n          ", "#text": "(5)"}, "@id": "H36CA9C8E91104E43A168D10BA4EE83EF", "#text": "\n          "}], "#text": "\n        ", "@id": "H30D6A88C6F1F49F19AE16E45FD5CC326"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and the ", "@entity-type": "committee", "#text": "Committee on Energy and Commerce of the House of\n\t\t\t Representatives", "@entity-id": "HIF00"}, {"#tail": " a report in an electronic format describing the specific\n\t\t\t recommendations of the Task Force for improving the access individual\n\t\t\t patients have to investigational drugs pursuant to ", "@entity-type": "committee", "#text": "Committee on Health, Education, Labor and Pensions\n\t\t\t of the Senate", "@entity-id": "SSHR00"}], "#text": "Not later than 180 days after the date on which the Task Force is convened, the Task Force shall\n\t\t\t submit to the ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "subsection (b) of\n\t\t\t section 561 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:561/ss:b"}, {"#tail": ")", "@entity-type": "uscode", "#text": "21 U.S.C.\n\t\t\t 360bbb", "@value": "usc/21/360bbb"}], "@entity-type": "law-citation", "#text": "\n            "}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(d)"}, "header": {"#tail": "\n        ", "#text": "Report"}, "#text": "\n        ", "@id": "HE1DB8F8371F446C6BA773C1C7AB6FEF4"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "The task force shall terminate upon submission of the report required under subsection (d)."}, "enum": {"#tail": "\n        ", "#text": "(e)"}, "header": {"#tail": "\n        ", "#text": "Termination"}, "#text": "\n        ", "@id": "HFFDE0D5B8D7A4D73B0616335429865F6"}], "#text": "\n      ", "@id": "H2ACA0B9BAF384374AFE218409D3F562D"}, {"#tail": "\n  ", "enum": {"#tail": "\n      ", "#text": "6."}, "header": {"#tail": "\n\t\t\t", "#text": "Finalizing draft guidance on expanded access"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " submits the report under subsection (d) of such section, the\n\t\t\t ", "@entity-type": "act", "#text": "section 5", "@value": "Andrea Sloan CURE Act/s:5", "@proposed": "true"}, {"#tail": " shall finalize the draft guidance\n\t\t\t entitled ", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}], "quote": {"#tail": " and dated May 2013.", "#text": "Expanded Access to Investigational Drugs for Treatment Use\u2014Qs & As"}, "#text": "Not later than 180 days after the date on which the Expanded Access Task Force established under\n\t\t\t ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In general"}, "#text": "\n        ", "@id": "H39648645B9FA4677B900DA9060367018"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t\t", "#text": "The final guidance referred to in subsection (a) shall\u2014"}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Contents"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " interprets and uses adverse drug event data reported by\n\t\t\t investigators in the case of data reported from use under a request\n\t\t\t submitted under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "clearly define how the ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": "; and", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t (", "@entity-type": "act", "#text": "section 561(b) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:561/ss:b"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 360bbb(b)", "@value": "usc/21/360bbb/b"}, "@parsable-cite": "usc/21/360bbb", "#text": "\n              ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "HDBF4D6C15E5A4DEB947D5DC07DD2D24D", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and the\n\t\t\t first report of the ", "@entity-type": "act", "#text": "section 5(d)", "@value": "Andrea Sloan CURE Act/s:5/ss:d", "@proposed": "true"}, {"#tail": " submitted\n\t\t\t under ", "@entity-type": "federal-body", "#text": "Comptroller General of the United States", "@entity-id": "0500"}, {"#tail": ".", "@entity-type": "act", "#text": "section 4", "@value": "Andrea Sloan CURE Act/s:4", "@proposed": "true"}], "#text": "take into account the report of the Expanded Access Task Force submitted under "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "H985407DD91C748BCB6DB5A75EA6B24D8", "#text": "\n          "}], "#text": "\n        ", "@id": "HA619440679EC48609B462B1E3DDFEF8F"}], "#text": "\n      ", "@id": "HBDC5E40B9AD0401A86C6027EC130A146"}], "#text": "\n\t\t", "@id": "HC04E52FE190A40F19CD97F9E0A4387C1"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2014-12-08"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 HR 5805 IH: Andrea Sloan CURE Act"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. House of Representatives"}, "#text": "\n"}, "#text": "\n"}}}